Nuvalent (NASDAQ:NUVL) CFO Sells $309,065.96 in Stock

Nuvalent, Inc. (NASDAQ:NUVL) CFO Alexandra Balcom sold 3,181 shares of the company’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $97.16, for a total transaction of $309,065.96. Following the transaction, the chief financial officer owned 81,733 shares of the company’s stock, valued at approximately $7,941,178.28. This represents a 3.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Alexandra Balcom also recently made the following trade(s):

• On Monday, January 5th, Alexandra Balcom sold 4,236 shares of Nuvalent stock. The shares were sold at an average price of $97.32, for a total transaction of $412,247.52.
• On Monday, December 8th, Alexandra Balcom sold 7,084 shares of Nuvalent stock. The stock was sold at an average price of $110.32, for a total transaction of $781,506.88.
• On Monday, November 17th, Alexandra Balcom sold 20,000 shares of Nuvalent stock. The shares were sold at an average price of $99.45, for a total value of $1,989,000.00.
• On Tuesday, November 18th, Alexandra Balcom sold 729 shares of Nuvalent stock. The stock was sold at an average price of $104.26, for a total value of $76,005.54.
• On Wednesday, October 15th, Alexandra Balcom sold 1,683 shares of Nuvalent stock. The stock was sold at an average price of $85.57, for a total value of $144,014.31.
• On Monday, October 13th, Alexandra Balcom sold 20,000 shares of Nuvalent stock. The shares were sold at an average price of $88.51, for a total value of $1,770,200.00.

Nuvalent Stock Performance

Shares of NASDAQ:NUVL traded up $9.62 during midday trading on Wednesday, hitting $106.82. 895,694 shares of the stock were exchanged, compared to its average volume of 779,373. The business’s 50-day moving average price is $102.57 and its 200 day moving average price is $88.78. Nuvalent, Inc. has a 12 month low of $55.53 and a 12 month high of $112.88. The stock has a market capitalization of $7.77 billion, a price-to-earnings ratio of -20.08 and a beta of 1.32.

Nuvalent (NASDAQ:NUVL) last posted its earnings results on Thursday, October 30th. The company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.39) by ($0.31). During the same period last year, the business posted ($1.28) EPS. As a group, sell-side analysts expect that Nuvalent, Inc. will post -3.86 EPS for the current year.

Key Stories Impacting Nuvalent

Here are the key news stories impacting Nuvalent this week:

• Negative Sentiment: CEO James Richard Porter sold 9,543 shares on Jan. 6 at an average $97.16 (≈ $927.2k); his post-sale holding was 278,629 shares (3.31% ownership drop). SEC Filing
• Negative Sentiment: CEO James Richard Porter sold 17,890 shares on Jan. 5 at an average $97.32 (≈ $1.74M); post-sale direct ownership 288,172 shares (5.85% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 81,733 shares (3.75% ownership drop). SEC Filing
• Negative Sentiment: CFO Alexandra Balcom sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 84,914 shares (4.75% ownership drop). SEC Filing
• Negative Sentiment: Insider Christopher Durant Turner sold 3,181 shares on Jan. 6 at $97.16 (≈ $309.1k); post-sale holding 55,130 shares (5.46% ownership drop). SEC Filing
• Negative Sentiment: Christopher Durant Turner sold 4,236 shares on Jan. 5 at $97.32 (≈ $412.2k); post-sale holding 58,311 shares (6.77% ownership drop). SEC Filing
• Negative Sentiment: Insider Deborah Ann Miller sold 2,589 shares on Jan. 6 at $97.16 (≈ $251.5k); post-sale holding 42,134 shares (5.79% ownership drop). SEC Filing
• Negative Sentiment: Deborah Ann Miller sold 4,363 shares on Jan. 5 at $97.32 (≈ $424.6k); post-sale holding 44,723 shares (8.89% ownership drop). SEC Filing
• Negative Sentiment: Insider Henry E. Pelish sold 2,664 shares on Jan. 6 at $97.17 (≈ $258.9k); post-sale holding 65,888 shares (3.89% ownership drop). SEC Filing
• Negative Sentiment: Henry E. Pelish sold 2,496 shares on Jan. 5 at $97.32 (≈ $242.9k); post-sale holding 68,552 shares (3.51% ownership drop). SEC Filing

Analysts Set New Price Targets

A number of analysts recently weighed in on the company. UBS Group restated a “buy” rating on shares of Nuvalent in a report on Wednesday, December 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research note on Wednesday, October 8th. Wedbush reaffirmed an “outperform” rating and issued a $125.00 price objective (up from $120.00) on shares of Nuvalent in a research note on Monday, November 17th. Stifel Nicolaus increased their target price on shares of Nuvalent from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Monday, November 17th. Finally, Barclays set a $152.00 price target on shares of Nuvalent in a report on Monday, November 17th. Fifteen research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Nuvalent has an average rating of “Moderate Buy” and an average price target of $138.33.

Institutional Investors Weigh In On Nuvalent

A number of hedge funds have recently added to or reduced their stakes in NUVL. GAMMA Investing LLC lifted its stake in Nuvalent by 47.6% in the fourth quarter. GAMMA Investing LLC now owns 335 shares of the company’s stock valued at $34,000 after buying an additional 108 shares during the period. US Bancorp DE increased its stake in shares of Nuvalent by 10.0% in the 3rd quarter. US Bancorp DE now owns 2,070 shares of the company’s stock valued at $179,000 after acquiring an additional 188 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of Nuvalent by 3.7% during the 2nd quarter. Kennedy Capital Management LLC now owns 5,504 shares of the company’s stock valued at $420,000 after acquiring an additional 196 shares during the period. Arizona State Retirement System lifted its position in shares of Nuvalent by 1.9% during the 3rd quarter. Arizona State Retirement System now owns 11,778 shares of the company’s stock valued at $1,019,000 after acquiring an additional 220 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in Nuvalent by 7.7% during the third quarter. Principal Financial Group Inc. now owns 3,290 shares of the company’s stock worth $285,000 after acquiring an additional 234 shares in the last quarter. 97.26% of the stock is currently owned by institutional investors.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.